Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 284-295

  Vu, Thuy C ^a   Nutt, John G ^b   Holford, Nicholas H G ^c  

^a AMGEN INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Disease progress; Levodopa; Parkinson's disease; Selegiline; Time to event; Time dependent covariate

Indexed keywords

LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; DEATH; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CHI-SQUARE DISTRIBUTION; COGNITION; COGNITION DISORDERS; DEPRESSION; DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PARKINSON DISEASE; PATIENT DROPOUTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SELEGILINE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOCOPHEROLS; TREATMENT OUTCOME;

EID: 84862606872     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04208.x     Document Type: Article

References (43)

1. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59: 1724-8.
2. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1839-51. quiz 988.
3. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707. quiz 837.
4. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602-7.
5. Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Maki-Ikola O, Rinne UK. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998; 51: 825-30.
6. Collett D. In: Modelling Survival Data in Medical Research, 2nd edn. Boca Raton, FL: CRC Press, 2003.
7. Lindsey JK. A study of interval censoring in parametric regression models. Lifetime Data Anal 1998; 4: 329-54.
8. Sparling YH, Younes N, Lachin JM, Bautista OM. Parametric survival models for interval-censored data with time-dependent covariates. Biostat 2006; 7: 599-614.
9. Duffull SB, Wright DFB, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol 2011; 71: 807-14.
10. Holford NH, Nutt JG. Interpreting the results of Parkinson's disease clinical trials: time for a change. Mov Disord 2011; 26: 569-77.
11. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43: 318-25.
12. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64: 87-93.
13. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989; 46: 1052-60.
14. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529-34.
15. Fahn S, Elton R. The unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's Disease, eds Fahn SMC, Calne DB, Goldstein M. Florham Park, NJ: Macmillan Healthcare Information, 1987; 153-63. 293-304.
16. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
18. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006; 21: 1200-7.
19. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-92.
20. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33: 281-311.
21. Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br J Clin Pharmacol 2012; 74: 267-83.
22. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-5.
23. Beal S, Sheiner L, Boeckmann A. NONMEM User's Guides. Ellicott City, MD: Icon Development Solutions, 19892009.
24. Garnett C, Holford NHG. Bone mineral density progression linked to dropout and time-to-fracture: application to postmenopausal women taking hormone replacement therapy. In: 5th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijkerhout, the Netherlands, 2006.
25. Björnsson MA, Simonsson USH. Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration. Br J Clin Pharmacol 2011; 71: 899-906.
26. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009; 86: 84-91.
27. R Development Core Team. R: a language and environment for statistical computing. In, 2.6 Edition, Vienna, Austria: R Foundation for Statistical Computing, 2007.
28. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-76.
29. Graham PL, Ryan LM, Luszcz MA. Joint modelling of survival and cognitive decline in the Australian Longitudinal Study of Ageing. J R Stat Soc Ser C Appl Stat 2011; 60: 221-38.
30. Song X, Davidian M, Tsiatis AA. A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data. Biometrics 2002; 58: 742-53.
31. Deslandes E, Chevret S. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia. Stat Med 2007; 26: 5411-21.
32. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21: 1123-30.
33. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-9.
34. Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191-6.
35. Thorogood M, Armstrong B, Nichols T, Hollowell J. Mortality in people taking selegiline: observational study. BMJ 1998; 317: 252-4.
36. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 228-34.
37. Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllyla VV. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 1997; 48: 662-7.
38. Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 1999; 14: 246-51.
39. Coyle J, Hobson P, Meara J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 280. author reply 81-2.
40. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922-35.
41. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730-6.
42. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-58.
43. Vu TC, Nutt JG, Holford NH. Time course of disease status as a predictor of clinical outcome in Parkinson's Disease. Available at (last accessed December 2010). In: PAGE, 2008: Abstr 1256.